Jim Cevallos: I've been a consumer of psychedelics since my early 20s. He worked as a quantitative researcher and portfolio manager at a number of different hedge funds throughout his 20s. In 2020, he was in the middle of COVID, sitting in his apartment doing this job that he liked, but didn't love. The timing was good because it just so happened that there were the first signs of life of a legitimate for profit industry starting to build around psychedelics.
Brom Rector is the founder of Empath Ventures, a VC fund that in invests in early-stage psychedelics startups. Prior to founding Empath, Brom sent several years as a portfolio manager and quantitative researcher. Brom joins the show to discuss the current state of the psychedelics industry, the lessons learned founding a VC fund, the differences between psychedelics and cannabis, and a whole lot more. Important Links:
Show Notes:
- How Brom became interested in psychedelic investing
- Psychedelics and the mental health epidemic
- Depoliticising psychedelics
- Empath Ventures’ business model
- How we can scientifically improve psychedelics
- The influence of hippie culture
- A contrarian view on Big Pharma
- The potential benefits of ibogaine
- The differences between cannabis and psychedelics
- Do some people not react to psychedelics?
- Brom’s thoughts on microdosing
- Lessons learned from founding a VC company
- The benefits of Rule 506(c)
Books Mentioned:
- How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence; by Michael Pollan
- Healing Back Pain: The Mind-Body Connection; by John E. Sarno MD